Eli Lilly and Company is a pharmaceutical company that discovers, develops, manufactures, and markets human pharmaceutical products. Incorporated in 1901 to succeed a drug manufacturing business founded in 1876, the company operates in a single business segment. Its product portfolio is organized into four therapeutic areas: cardiometabolic health, oncology, immunology, and neuroscience. Key products include Mounjaro and Zepbound for diabetes and obesity, Jardiance and Trulicity for cardiometabolic conditions, and Humalog and Humulin for insulin therapy. In oncology, the company markets Cyramza, Erbitux, Retevmo, and Verzenio. Immunology products include Taltz, Olumiant, and Omvoh, while neuroscience offerings feature Emgality and Kisunla. The company collaborates with partners such as Boehringer Ingelheim, Incyte Corporation, Innovent Biologics, and Almirall S.A. for specific products. Eli Lilly manufactures and distributes its medicines through facilities in the United States, Europe, and Asia, selling in multiple countries. In the U.S., distribution is primarily through wholesalers, and the company utilizes LillyDirect, a direct-to-patient digital healthcare platform, for medicine delivery and patient support.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Drug Manufacturers - General Homepage lilly.com
Sector Healthcare IR page lilly.com
Tags
cardiometabolic health, oncology, immunology, neuroscience, diabetes, obesity, insulin, glp-1 receptor agonists, sglt2 inhibitors, cancer therapy, autoimmune diseases, alzheimer's disease, Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity, Zepbound, Cyramza, Erbitux, Inluriyo, Jaypirca, Retevmo, Tyvyt, Verzenio, Ebglyss, Olumiant, Omvoh, Taltz, Emgality, Kisunla, LillyDirect
Press page lilly.com/jp/news/stories

Metrics

Valuation  
Market cap $ 1.319T
Market cap (USD) $ 1.319T
P/E 45.52
PEG 0.93
P/BV 32.76
P/S 15.26
P/OCF 43.06
P/FCF 221.23
Dividend yield 0.44%
Turnover / mcap —
Returns  
ROE 101.4%
ROI 29.9%
ROIC 34.5%
Profit margin 31.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 49.0%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 122.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 24
Quality score 36.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 65.179B 45.043B 34.124B 28.541B 28.318B 24.54B 22.32B 24.556B 22.871B 21.222B 19.959B 19.616B 23.113B 22.603B 24.287B 23.076B 21.836B 20.378B 18.634B 15.691B 14.645B 13.858B 12.583B 11.078B 11.543B —
Net profit 20.64B 10.59B 5.24B 6.245B 5.582B 6.194B 8.318B 3.232B -204.1M 2.738B 2.408B 2.391B 4.685B 4.089B 4.348B 5.07B 4.329B -2.072B 2.953B 2.663B 1.98B 1.81B 2.561B 2.708B — 3.058B
Free cash flow 5.964B 414M -3.152B 4.6B 5.388B — — — — — — — — — — — — 6.348B 4.072B 2.898B 615.5M 971.4M 1.94B 939.8M 2.778B 3.054B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 1.075K 772 582.92 365.84 276.22 168.84 131.43 115.72 84.46 73.55 84.26 68.99 51 49.32 41.56 35.04 35.71 40.27 57.35 54.12 — — — — — —
Price performance 12m 0.39 0.32 0.59 0.32 0.64 0.28 0.14 0.37 0.15 -0.13 0.22 0.35 0.03 0.19 0.19 -0.02 -0.11 -0.3 0.06 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 4.03B 4.55B 5.25B 4.55B 5.88B 6.67B 6.9B 9.09B 11B 17.8B
↳ YoY growth +14.7% +12.8% +15.4% -13.3% +29.2% +13.6% +3.3% +31.8% +21.1% +61.4%
↳ 5y CAGR +2.3% +6.4% +8.8% +7.0% +10.8% +10.6% +8.7% +11.6% +19.3% +24.8%
Borrowings, current (USD) 1.3B 2.7B 499M 1.49B 0.00 1.54B 1.5B 6.19B 4.34B 0.00
Borrowings, non-current (USD) 8.37B 9.94B 11.6B 13.8B 16.6B 15.3B 14.7B 18.3B 28.5B 40.9B
Lease liabilities (USD) — — 595M 487M 664M 686M 728M 1.11B 1.15B 1.36B
Cash and deposits (USD) 4.58B 6.54B 8B 2.34B 3.66B 3.82B 2.07B 2.82B 3.27B 7.27B
Intangible assets (USD) 4.36B 4.03B 3.52B 6.62B 7.45B 7.69B 7.21B 6.91B 6.17B 6.52B
Right-of-use assets (USD) — — 530M 532M — — — 1.02B 1.05B 1.26B
Net debt (borrowings + leases - cash) (USD) 5.09B 6.1B 4.14B 13.5B 13.6B 13.8B 14.9B 22.8B 30.7B 35B
Cash flow detail
Operating cash flow (USD) 4.85B 5.62B 5.52B 4.84B 6.5B 7.26B 7.08B 4.24B 8.82B 16.8B
Purchases of intangible assets (USD) 0.00 — -1.98B -240M -660M -875M — — — —
Change in inventories (cash effect) (USD) -328M -254M 7.8M -259M -533M -236M -600M -1.43B -2.51B -4.67B
Change in payables (cash effect) (USD) 819M 916M -285M -478M 1.27B -664M 1.33B 4.27B 2.61B 10.2B
Dividends paid (cash effect) (USD) -2.16B -2.19B -2.31B -2.41B -2.69B -3.09B -3.54B -4.07B -4.68B -5.38B
Share buybacks (cash effect) (USD) -600M -300M -4.15B -4.4B -500M -1.25B -1.5B -750M -2.5B -4.11B
Interest paid (cash effect) (USD) -146M -193M -224M -306M -346M -338M -324M -404M -578M -633M
Income taxes paid (cash effect) (USD) -701M -247M -1.1B -1.18B -955M -1.6B -2.67B -5.56B -6.56B -10.8B
Share-based compensation (USD) 255M 281M 280M 312M 308M 343M 371M 629M 646M 626M
Income detail
Research and development expense (USD) 5.24B 5.28B 5.31B 5.6B 6.09B 7.03B 7.19B 9.31B 11B 13.3B
↳ 5y CAGR +0.9% +0.0% -0.8% +3.4% +4.9% +6.0% +6.4% +11.9% +14.5% +17.0%
Total comprehensive income (USD) 2.09B -29.6M 3.32B 7.54B 6.22B 7.74B 6.74B 4.76B 10.6B 22.1B
Comprehensive income to owners (USD) 2.09B — — — 6.22B 7.74B 6.74B 4.76B 10.6B 22.1B
Reported Feb 21, 2017 Feb 20, 2018 Feb 17, 2021 Feb 17, 2021 Feb 22, 2023 Feb 22, 2023 Feb 22, 2023 Feb 19, 2025 Feb 19, 2025 Feb 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated October 29, 2026, announcing the financial results of Eli Lilly and Company for the quarter ended September 30, 2026.

Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated August 5, 2026, announcing the financial results of Eli Lilly and Company for the quarter ended June 30, 2026.

Eli Lilly and Company — Other Events Bull 0 Bear 0 Routine

On May 20, 2026, Eli Lilly and Company (the “Company”) completed its offering of $750,000,000 aggregate principal amount of its Floating Rate Notes due 2028 (the “2028 Floating Rate Notes”), $500,000,000 aggregate principal amount of its Floating Rate Notes due 2029 (the “2029 Floating Rate Notes” and, together with the 2028 Floating Rate Notes, the “Floating Rate Notes”), $750,000,000 aggregate principal amount of its 4.150% Notes due 2029 (the “2029 Notes”), $1,500,000,000 aggregate principal amount of its 4.375% Notes due 2031 (the “2031 Notes”), $1,250,000,000 aggregate principal amount of its 4.650% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of its 4.850% Notes due 2036 (the “2036 Notes”), $1,750,000,000 aggregate principal amount of its 5.600% Notes due 2056 (the “2056 Notes”) and $1,000,000,000 aggregate principal amount of its 5.700% Notes due 2066 (the “2066 Notes” and, collectively with the 2029 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2056 Notes, the “Fixed Rate Notes,” and together with the Floating Rate Notes, the “Notes”).

Prompts

Eli Lilly and Company (ticker LLY), listed in United States.

Company History

Date Change Detail
Oct 28, 2019 Renamed LILLY ELI & CO → ELI LILLY & CO

ETFs Holding Eli Lilly and Company

ETF Weight in ETF Shares Market value As of
MEDI 21.10% 6,543 $ 9.327M Nov 12, 2026
OZEM 20.49% 8,083 $ 11.442M Nov 17, 2026
MEDX 18.46% 2,936 $ 3.522M Jun 30, 2026
TMED 16.71% 3,209 $ 3.849M Jun 30, 2026
GDOC 12.19% 2,066 $ 2.39M Aug 31, 2026
HRTS 11.11% 5,343 $ 6.18M Aug 31, 2026
JDOC 8.78% 613 $ 867.732K Nov 17, 2026
GK 8.75% 1,727 $ 2.445M Nov 17, 2026
PCLG 6.99% 5,045 $ 5.796M Jul 31, 2026
VNSE 6.99% 823 $ 987.131K Jun 30, 2026
PSIL 6.91% 1,860 $ 2.633M Nov 17, 2026
DUNK 6.56% 7,596 $ 10.875M Nov 17, 2026
EASY 5.92% 3,134 $ 3.6M Jul 31, 2026
PJFG 5.69% 5,187 $ 7.342M Nov 18, 2026
PINK 5.59% 13,210 $ 18.699M Nov 17, 2026
HFGO 5.50% 6,088 $ 0.00 Nov 18, 2026
CARK 5.46% 15,162 $ 17.419M Jul 31, 2026
VGRO 5.39% 176 $ 202.196K Jul 31, 2026
DUHP 5.38% 735,353 $ 1.05B Nov 12, 2026
GDIV 5.20% 8,721 $ 12.589M Nov 13, 2026
CANC 5.15% 9,404 $ 10.878M Aug 31, 2026
ARKG 5.04% 64,741 $ 91.644M Nov 18, 2026
EGGY 5.00% 4,256 $ 6.093M Nov 17, 2026
SXQG 4.97% 2,079 $ 2.964M Nov 12, 2026
PCGG 4.97% 238 $ 285.464K Jun 30, 2026
SEMG 4.94% 2,146 $ 3.04M Nov 18, 2026
FCTE 4.93% 10,050 $ 12.054M Jun 30, 2026
LOGO 4.81% 1,070 $ 1.532M Nov 17, 2026
WINN 4.80% 39,581 $ 57.135M Nov 13, 2026
FRIZ 4.66% 204 $ 244.684K Jun 30, 2026
FMKT 4.63% 318 $ 455.271K Nov 17, 2026
BKCG 4.61% 4,808 $ 5.524M Jul 31, 2026
JGRW 4.58% 3,477 $ 4.022M Aug 31, 2026
PGRO 4.56% 8,361 $ 9.671M Aug 31, 2026
USSE 4.52% 13,511 $ 16.205M Jun 30, 2026
BRIF 4.43% 5,703 $ 6.84M Jun 30, 2026
BAMG 4.40% 4,871 $ 5.634M Aug 31, 2026
CAPE 4.38% 8,716 $ 10.454M Jun 30, 2026
EGGQ 4.37% 1,796 $ 2.571M Nov 17, 2026
BGRO 4.32% 264 $ 377.961K Nov 16, 2026
ILDR 4.29% 9,515 $ 13.622M Nov 16, 2026
RILA 4.27% 1,568 $ 1.801M Jul 31, 2026
GGRW 4.23% 309 $ 370.624K Jun 30, 2026
BWTG 4.08% 727 $ 840.943K Aug 31, 2026
AVIE 4.06% 472 $ 675.748K Nov 16, 2026
CGUS 4.00% 336,007 $ 481.051M Nov 16, 2026
GFGF 3.95% 1,128 $ 1.305M Aug 31, 2026
NUGO 3.95% 83,920 $ 96.411M Jul 31, 2026
AFOS 3.90% 7,574 $ 10.72M Nov 18, 2026
SCLZ 3.88% 635 $ 761.638K Jun 30, 2026
VSLU 3.69% 16,801 $ 20.152M Jun 30, 2026
TGRT 3.64% 40,817 $ 58.436M Nov 17, 2026
PJFV 3.63% 6,847 $ 9.692M Nov 18, 2026
CLCG 3.59% 884 $ 1.016M Jul 31, 2026
REGS 3.58% 1,936 $ 2.322M Jun 30, 2026
GROZ 3.54% 3,532 $ 4.086M Aug 31, 2026
JXX 3.51% 815 $ 936.305K Jul 31, 2026
WLTG 3.50% 2,343 $ 2.692M Jul 31, 2026
QDVO 3.49% 21,500 $ 25.788M Jun 30, 2026
SGRT 3.46% 1,314 $ 1.881M Nov 17, 2026
HBTA 3.44% 7,343 $ 8.494M Aug 31, 2026
RSMV 3.42% 704 $ 844.399K Jun 30, 2026
NANC 3.35% 6,334 $ 9.068M Nov 17, 2026
FFLG 3.34% 17,155 $ 19.708M Jul 31, 2026
JGRO 3.29% 208,805 $ 295.574M Nov 17, 2026
AVUQ 3.28% 9,716 $ 13.91M Nov 16, 2026
BIGY 3.28% 642 $ 919.132K Nov 17, 2026
CGGR 3.26% 572,848 $ 820.129M Nov 16, 2026
BCGD 3.17% 258 $ 309.453K Jun 30, 2026
NQLT 3.14% 1,328 $ 1.536M Aug 31, 2026
LOTI 3.08% 1,260 $ 1.448M Jul 31, 2026
CGCV 3.08% 52,881 $ 75.708M Nov 16, 2026
SAWG 3.03% 76 $ 87.312K Jul 31, 2026
HGRO 3.01% 3,308 $ 3.8M Jul 31, 2026
NBGX 2.97% 382 $ 441.871K Aug 31, 2026
BBLU 2.97% 10,352 $ 14.65M Nov 18, 2026
ABFL 2.96% 13,534 $ 15.548M Jul 31, 2026
HELX 2.95% 688 $ 825.208K Jun 30, 2026
BDIV 2.93% 170 $ 195.303K Jul 31, 2026
SPCT 2.88% 1,685 $ 1.936M Jul 31, 2026
GPT 2.83% 559 $ 670.481K Jun 30, 2026
XMAG 2.79% 4,219 $ 6.014M Nov 13, 2026
ESLG 2.77% 560 $ 643.35K Jul 31, 2026
CCOR 2.75% 668 $ 767.425K Jul 31, 2026
ACGR 2.75% 249 $ 288.026K Aug 31, 2026
ZECP 2.72% 8,848 $ 10.235M Aug 31, 2026
FBCG 2.71% 163,157 $ 187.441M Jul 31, 2026
FDG 2.68% 9,725 $ 11.249M Aug 31, 2026
MPLY 2.61% 361 $ 414.731K Jul 31, 2026
ALRG 2.55% 186 $ 213.684K Jul 31, 2026
SPIN 2.55% 793 $ 1.135M Nov 16, 2026
DARP 2.53% 485 $ 694.36K Nov 17, 2026
QLTY 2.53% 113,212 $ 130.956M Aug 31, 2026
USMC 2.53% 73,514 $ 88.175M Jun 30, 2026
LCAP 2.52% 38,404 $ 46.063M Jun 30, 2026
FELG 2.52% 118,478 $ 142.106M Jun 30, 2026
SAMM 2.45% 621 $ 744.846K Jun 30, 2026
SAMT 2.42% 17,684 $ 21.211M Jun 30, 2026
SMRI 2.37% 11,648 $ 16.49M Nov 18, 2026
INFO 2.30% 15,275 $ 22.049M Nov 13, 2026